Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/MDER.S145651 http://scihub22266oqcxt.onion/10.2147/MDER.S145651 C5846302!5846302!29563844     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Devices+(Auckl) 2018 ; 11 (ä): 65-75 Nephropedia Template TP {{tp|p=29563844|t=2018. A randomized, controlled trial of Veriset? hemostatic patch in halting cardiovascular bleeding |pdf=|usr=}}{{29563844}} gab.com Text A randomized, controlled trial of Veriset hemostatic patch in halting cardiovascular bleeding JO: Med Devices (Auckl) http://www.kidney.de/pget.php?&tw=1&pmid=29563844 #FOAvip Background: Obtaining hemostasis during cardiovascular procedures can be a challenge, particularly around areas with a complex geometry or that are difficult to access. While several topical hemostats are currently on the market, most have caveats that limit their use in certain clinical scenarios such as pulsatile arterial bleeding. The aim of this study was to assess the effectiveness and safety of Veriset? hemostatic patch in treating cardiovascular bleeding. Methods: Patients (N=90) scheduled for cardiac or vascular surgery at 12 European institutions were randomized 1:1 to treatment with either Veriset? hemostatic patch (investigational device) or TachoSil® (control). After application of the hemostat, according to manufacturer instructions for use, time to hemostasis was monitored. Follow-up occurred up to 90 days post-surgery. Results: Median time to hemostasis was 1.5 min with Veriset? hemostatic patch, compared to 3.0 min with TachoSil® (p<0.0001). Serious adverse events within 30 days post-surgery were experienced by 12/44 (27.3%) patients treated with Veriset? hemostatic patch and 10/45 (22.2%) in the TachoSil® group (p=0.6295). None of these adverse events were device-related, and no reoperations for bleeding were required within 5 days post-surgery in either treatment group. Conclusion: This study reinforces the difference in minimum recommended application time between Veriset? hemostatic patch and TachoSil® (30 s versus 3 min respectively). When compared directly at 3 min, Veriset? displayed no significant difference, showing similar hemostasis and safety profiles on the cardiovascular bleeding sites included in this study. Twit Text FOAVip A randomized, controlled trial of Veriset hemostatic patch in halting cardiovascular bleeding ????Med Devices (Auckl) http://www.kidney.de/pget.php?&tw=1&pmid=29563844 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29563844 #FOAvip English Wikipedia <ref>{{Cite pmid|29563844}}</ref> A randomized, controlled trial of Veriset? hemostatic patch in halting cardiovascular bleeding #MMPMID29563844 Glineur D; Hendrikx M; Krievins D; Stradins P; Voss B; Waldow T; Haenen L; Oberhoffer M; Ritchie CM Med Devices (Auckl) 2018[]; 11 (ä): 65-75 PMID29563844show ga Background: Obtaining hemostasis during cardiovascular procedures can be a challenge, particularly around areas with a complex geometry or that are difficult to access. While several topical hemostats are currently on the market, most have caveats that limit their use in certain clinical scenarios such as pulsatile arterial bleeding. The aim of this study was to assess the effectiveness and safety of Veriset? hemostatic patch in treating cardiovascular bleeding. Methods: Patients (N=90) scheduled for cardiac or vascular surgery at 12 European institutions were randomized 1:1 to treatment with either Veriset? hemostatic patch (investigational device) or TachoSil® (control). After application of the hemostat, according to manufacturer instructions for use, time to hemostasis was monitored. Follow-up occurred up to 90 days post-surgery. Results: Median time to hemostasis was 1.5 min with Veriset? hemostatic patch, compared to 3.0 min with TachoSil® (p<0.0001). Serious adverse events within 30 days post-surgery were experienced by 12/44 (27.3%) patients treated with Veriset? hemostatic patch and 10/45 (22.2%) in the TachoSil® group (p=0.6295). None of these adverse events were device-related, and no reoperations for bleeding were required within 5 days post-surgery in either treatment group. Conclusion: This study reinforces the difference in minimum recommended application time between Veriset? hemostatic patch and TachoSil® (30 s versus 3 min respectively). When compared directly at 3 min, Veriset? displayed no significant difference, showing similar hemostasis and safety profiles on the cardiovascular bleeding sites included in this study. äA randomized, controlled trial of Veriset? hemostatic patch in halting(epmc).pdf DeepDyve Pubget Overpricing